Last week's SynBioBeta conference was indicative of the high degree of interest in the synthetic bio space from omics research tool vendors.
This week's news includes Adaptive Biotechnologies, Thermo Fisher Scientific, TATAA Biocenter, and New England Biolabs.
The new partnership will support the analysis of glycans in 30,000 human samples by the end of 2021.
New England Biolabs is using Avacta's affimers with a development-stage research and diagnostic assay that could launch as early as next year.
The partnership will allow customers using NEBNext Direct target enrichment products to analyze data with the Bluebee platform.
The two companies will work to characterize new Cas nucleases, and NEB will then manufacture and commercially distribute the nucleases globally.
The services will couple NEB's reagents and expertise in enzyme development and manufacturing with TTP's Desktop Biology product development and engineering know-how.
Researchers outlined the "nicking enzyme-assisted sequencing" (NicE-seq) protocol and presented results from proof-of-principal open chromatin profiling experiments.
In Science this week: intellectual property landscape of CRISPR genome editing, and more.
Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.
University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.
NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.
In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.